Unknown

Dataset Information

0

Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.


ABSTRACT: Aneusomy 17 causes inconsistency in fluorescence in situ hybridization (FISH)-based human epidermal growth factor receptor (HER)-2 status assessment using different algorithms (copy number or the HER-2/centromere enumerator probe 17 [CEP-17] ratio). We investigated the effects of FISH-based HER-2 status assessment and aneusomy 17 on responsiveness to neoadjuvant chemotherapy (NAC).This prospective study recruited 152 patients with locally advanced breast cancer who underwent four-cycle weekly paclitaxel plus carboplatin without trastuzumab.The pathologic complete remission (pCR) rate in the breast and axilla was 24.3% (95% confidence interval [CI], 17.7%-32.0%). Although HER-2 status, assessed by either HER-2/CEP-17 ratio-based FISH or copy number-based FISH, was a predictor of NAC sensitivity, ratio-assessed HER-2 status had a poorer performance in determining patients' responsiveness to NAC (p = .029). Patients who were not HER-2 amplified when assessed using the HER-2/CEP-17 ratio but were HER-2 amplified when assessed using copy number (~5%) were eventually proven to be responsive to NAC, with a pCR rate of 57% (95% CI, 18.4%-90.1%). In contrast, patients who were HER-2 amplified when assessed by the ratio but not HER-2 amplified when assessed using copy number (~3%) were completely irresponsive. Higher HER-2 copy numbers represented increasing chances of a pCR (adjusted odds ratio, 3.09; 95% CI, 1.35-7.08), with an apparent gene-dose effect (p for trend < .001).It is likely that HER-2 copy number but not the HER-2/CEP-17 ratio determines NAC sensitivity. Additional studies to validate our findings are warranted.

SUBMITTER: Yu KD 

PROVIDER: S-EPMC3380878 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.

Yu Ke-Da KD   Liu Guang-Yu GY   Zhou Xiao-Yan XY   Zhou Ying Y   Wu Jiong J   Chen Can-Ming CM   Shen Zhen-Zhou ZZ   Shao Zhi-Ming ZM  

The oncologist 20120504 6


<h4>Purpose</h4>Aneusomy 17 causes inconsistency in fluorescence in situ hybridization (FISH)-based human epidermal growth factor receptor (HER)-2 status assessment using different algorithms (copy number or the HER-2/centromere enumerator probe 17 [CEP-17] ratio). We investigated the effects of FISH-based HER-2 status assessment and aneusomy 17 on responsiveness to neoadjuvant chemotherapy (NAC).<h4>Patients and methods</h4>This prospective study recruited 152 patients with locally advanced bre  ...[more]

Similar Datasets

| S-EPMC8020003 | biostudies-literature
2010-05-26 | E-GEOD-10129 | biostudies-arrayexpress
2008-01-17 | GSE10129 | GEO
| S-EPMC8101236 | biostudies-literature
| S-EPMC3082892 | biostudies-other
| S-EPMC4445249 | biostudies-literature
| S-EPMC6232091 | biostudies-literature
| S-EPMC4221197 | biostudies-literature
| S-EPMC2873383 | biostudies-literature
2011-05-11 | E-GEOD-25066 | biostudies-arrayexpress